Nasal Technology

Platform devices for convenient delivery of intranasal dry powder

Reusable device with disposable nosepieces

The nosepieces are prefilled. Nosepiece is placed into the reusable device body and the plunger is pushed to release the dry powder drug.

Ready-to-use device prefilled with the drug

The nosepiece is placed in the nostril and the plunger is pushed to release the dry powder drug into the nasal cavity.

Reusable device for preclinical use

Autoclavable device components, disposable syringe and nosepiece. Used for research purposes only.

    • Therakind can offer the DriDose® platform in a co-development framework, where Therakind formulates partner's candidate into dry powder optimised for nasal delivery, and performs a proof-of-concept preclinical study using the appropriate nasal device.

    • Although the initial feasility work is performed under a fee-for-service model, Therakind can offer flexible collaboration model based on its internal evaluation.

    • Powder has potentially higher thermostability compared to liquid.

    • Convenient route of administration.

    • Self-administered: simple to operate with no specialist training.

    • Rapid onset as it bypasses first-pass metabolism.

    • No sharp waste.

  • • Simple to operate- can be used one-handed

    • Dose immediately available without reconstitution

    • No inhalation required- patient can be unconscious

    • Does not require aerosol

    • Available in unit and multi-dose formats

    • Suitable for automated filling and assembly

    • Patent protected